Leerink Partnrs Has Pessimistic View of PTCT Q1 Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Analysts at Leerink Partnrs dropped their Q1 2026 earnings per share estimates for shares of PTC Therapeutics in a research note issued to investors on Wednesday, October 15th. Leerink Partnrs analyst J. Schwartz now expects that the biopharmaceutical company will post earnings per share of ($1.40) for the quarter, down from their prior forecast of ($1.32). The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share. Leerink Partnrs also issued estimates for PTC Therapeutics’ Q2 2026 earnings at ($1.40) EPS, Q3 2026 earnings at ($0.74) EPS, Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($3.47) EPS and FY2027 earnings at ($3.82) EPS.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.24. PTC Therapeutics had a negative return on equity of 106.31% and a net margin of 35.65%.The firm had revenue of $178.88 million during the quarter, compared to analyst estimates of $173.01 million. During the same period last year, the company posted ($1.29) EPS. The business’s quarterly revenue was down 4.2% compared to the same quarter last year. PTC Therapeutics has set its FY 2025 guidance at EPS.

A number of other brokerages have also commented on PTCT. Wells Fargo & Company initiated coverage on PTC Therapeutics in a research report on Monday. They set an “overweight” rating and a $73.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and set a $118.00 price objective on shares of PTC Therapeutics in a research report on Wednesday, September 3rd. Citigroup raised their price objective on PTC Therapeutics from $40.00 to $50.00 and gave the stock a “neutral” rating in a research report on Monday, July 28th. Morgan Stanley decreased their price objective on PTC Therapeutics from $76.00 to $71.00 and set an “overweight” rating for the company in a research report on Wednesday, August 20th. Finally, Bank of America decreased their price objective on PTC Therapeutics from $82.00 to $76.00 and set a “buy” rating for the company in a research report on Wednesday, August 20th. Nine investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $69.00.

PTC Therapeutics Trading Up 3.7%

Shares of NASDAQ PTCT opened at $68.36 on Monday. PTC Therapeutics has a one year low of $35.95 and a one year high of $69.48. The firm has a market capitalization of $5.43 billion, a PE ratio of 9.81 and a beta of 0.55. The business has a 50-day moving average price of $57.89 and a two-hundred day moving average price of $51.29.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in PTCT. Nuveen LLC bought a new position in shares of PTC Therapeutics in the 1st quarter valued at approximately $51,427,000. Wellington Management Group LLP raised its stake in shares of PTC Therapeutics by 13.2% in the 1st quarter. Wellington Management Group LLP now owns 5,419,172 shares of the biopharmaceutical company’s stock valued at $276,161,000 after acquiring an additional 632,049 shares in the last quarter. Hood River Capital Management LLC raised its stake in shares of PTC Therapeutics by 654.4% in the 2nd quarter. Hood River Capital Management LLC now owns 636,502 shares of the biopharmaceutical company’s stock valued at $31,087,000 after acquiring an additional 552,130 shares in the last quarter. State Street Corp raised its stake in shares of PTC Therapeutics by 22.1% in the 2nd quarter. State Street Corp now owns 2,996,454 shares of the biopharmaceutical company’s stock valued at $146,347,000 after acquiring an additional 541,558 shares in the last quarter. Finally, Driehaus Capital Management LLC raised its stake in shares of PTC Therapeutics by 45.3% in the 1st quarter. Driehaus Capital Management LLC now owns 1,512,645 shares of the biopharmaceutical company’s stock valued at $77,084,000 after acquiring an additional 471,586 shares in the last quarter.

Insider Activity at PTC Therapeutics

In related news, Director David P. Southwell sold 12,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $58.34, for a total value of $700,080.00. Following the transaction, the director directly owned 16,850 shares of the company’s stock, valued at approximately $983,029. This trade represents a 41.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Neil Gregory Almstead sold 55,000 shares of the firm’s stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $66.05, for a total value of $3,632,750.00. Following the completion of the transaction, the insider directly owned 100,625 shares in the company, valued at $6,646,281.25. The trade was a 35.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 249,735 shares of company stock worth $15,467,670. 5.50% of the stock is currently owned by corporate insiders.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.